WASHINGTON, July 15 (Xinhua) – The New England Journal of Medicine reported that the follow-up to the 19-year-old Kovid vaccine was based on the results of an online publication on Tuesday. Named mRNA-1273, it generally works well and improves the activity of antibodies that contribute to the health of adults.

The follow-up diagnosis for Step 1 is supported by the American Institute for Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The vaccine was developed in collaboration with researchers from the NIAID and the US biological company Moderna, which activated the antibody directly against the coronavirus, a destructive protein that the virus uses to bind to the virus. "Human cells."

The judgment, led by the Washington Institute of Health Research in Seattle, began March 16 when the first candidate to be vaccinated.

A detailed search report begins with the first 45 participants, aged 18 to 55, who participated in research sites in Seattle and Emory University in Atlanta.

Three groups of 15 participants received two intramuscular injections, separately for 28 days and 25 days for follow-up of 100 or 200 micrograms of the vaccine.

In April, the verdict was extended for adult participants over the age of 55, and now has 120 participants.

There were no immediate reports of injuries. The study confirmed this. More than half of the participants experienced fatigue, headache, chills, muscle aches, or pain at the injection site. It is not uncommon for events to occur after a second vaccination and in those who have received high doses.

The second phase of the mRNA-1273 trial in support of Moderna began in late May.

Moderna plans to begin judging its final vaccine test on July 27. Translated by: Mao Bopha Makara